Daily Bio News Summary — 2026-08-26: FDA Approvals, Cancer Vaccines, and Biotech Deals Dominate
Twenty articles from eight sources covering FDA approvals in pancreatic cancer and gastric cancer, biotech dealmaking including Biohaven's $795M epilepsy alliance and ARCH/Haisco's China expansion, gene therapy setbacks for Regenxbio, and new clinical data for Argenx's Vyvgart.
Today’s harvest draws 20 articles from eight sources — BioSpace, STAT News, Endpoints News, BioPharma Dive, FDA Newsroom, PR Newswire, Reuters, and Pharmaphorum — with a heavy lean toward regulatory milestones and dealmaking.
FDA Activity
The FDA was busy today. The agency approved a first-in-class targeted therapy for metastatic pancreatic cancer (FDA Newsroom, 2026-08-26), a significant advance for one of the hardest-to-treat cancer types. Jazz Pharmaceuticals also secured a frontline gastric cancer approval for Ziihera, which analysts see as a potential blockbuster (Endpoints News, 2026-08-25; BioSpace, 2026-08-26). Meanwhile, Roche and Eli Lilly received FDA clearance for a new Alzheimer’s blood test, expanding diagnostic options for the neurodegenerative disease (BioPharma Dive, 2026-08-25).
On the regulatory setback side, Regenxbio was hit with another clinical hold for its Hunter syndrome gene therapy program (Endpoints News, 2026-08-25; BioPharma Dive, 2026-08-25), raising ongoing safety concerns about the gene therapy platform.
Deals and Partnerships
Dealmaking was active across the sector. Biohaven could receive up to $795 million through an epilepsy drug alliance with South Korea’s SK Biopharmaceuticals (BioSpace, 2026-08-26). ARCH Venture Partners and Population Health Partners joined the China biotech investment wave through a new deal with Haisco (Endpoints News, 2026-08-25). Roche committed to lean-mass preservation in its obesity pipeline through a new partnership with Hanmi Pharmaceutical (BioPharma Dive, 2026-08-25). And BMS ended its manufacturing partnership with Cellares over cell therapy production problems, triggering layoffs (BioSpace, 2026-08-26).
Clinical Data
Argenx shares jumped on positive Phase 3 data for its blockbuster drug Vyvgart (BioPharma Dive, 2026-08-07), reinforcing the drug’s growth trajectory. Vivace Therapeutics is strengthening its leadership team as it prepares to advance VT3989, the first TEAD inhibitor to enter Phase 3 trials for mesothelioma (PR Newswire, 2026-08-26).
Regulatory and Policy
A D.C. judge rejected Merck’s challenge to the Inflation Reduction Act’s drug pricing provisions more than three years after the case was filed (Endpoints News, 2026-08-25). ReviR Therapeutics received FDA Rare Pediatric Disease Designation for RTX-117 in Charcot-Marie-Tooth disease (PR Newswire, 2026-08-26). Spineart and eCential Robotics received FDA 510(k) clearance for the Perla TL application for robotic spinal procedures (PR Newswire, 2026-08-26).
What This Batch Is NOT Telling Us
Today’s harvest is notably light on AI-bio news, IPO activity, and large-scale M&A. The oral obesity race between Lilly and Novo Nordisk — a dominant theme in recent weeks — appears only indirectly through the Roche-Hanmi deal. No major clinical readouts in neuroscience or rare disease beyond the Regenxbio hold.
Reading Order
For limited-time readers, the highest-signal items today are:
- FDA approves first-in-class targeted therapy for metastatic pancreatic cancer — a genuine first for a difficult cancer type
- Jazz’s Ziihera wins frontline gastric cancer — potential blockbuster expansion
- Biohaven’s $795M epilepsy alliance with SK Bio — significant dealmaking signal
- Regenxbio hit with another clinical hold — ongoing gene therapy safety concerns
- Argenx Phase 3 Vyvgart data — blockbuster drug continues to deliver
Sources
All articles sourced from the daily biopharma-news-harvest on 2026-08-26. Full sourceUrls available in src/content/news/ for each article listed below.
- BMS ends Cellares pact over cell therapy production problems, triggering layoffs (BioSpace, 2026-08-26)
- Biohaven could get up to $795M in epilepsy alliance with SK Bio (BioSpace, 2026-08-26)
- On the fence about a statin? Calcium scans could be a tiebreaker (STAT News, 2026-08-26)
- Pennsylvania reports first 2 measles deaths in the U.S. this year (STAT News, 2026-08-25)
- Newer shingles vaccine linked to lower heart disease risk (STAT News, 2026-08-26)
- Nurse practitioner trainees stymied by shortage of clinical mentors (STAT News, 2026-08-24)
- J&J’s Imaavy wins label expansion; Two approvals in Japan (Endpoints News, 2026-08-25)
- ARCH and Population Health join China blitz with Haisco deal (Endpoints News, 2026-08-25)
- FDA approves Jazz’s Ziihera in frontline gastric cancer (Endpoints News, 2026-08-25)
- DC judge rejects Merck’s IRA case more than three years after it was filed (Endpoints News, 2026-08-25)
- Regenxbio hit with another clinical hold for Hunter syndrome gene therapy (Endpoints News, 2026-08-25)
- ReviR Therapeutics Receives FDA Rare Pediatric Disease Designation (PR Newswire, 2026-08-26)
- 4Sight Labs Expands OptiGuard to Cover Shared Cells (PR Newswire, 2026-08-26)
- Vivace Therapeutics Strengthens Leadership Team (PR Newswire, 2026-08-26)
- Spineart and eCential Robotics receive FDA 510(k) clearance (PR Newswire, 2026-08-26)
- FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer (FDA Newsroom, 2026-08-26)
- Roche, Eli Lilly get FDA nod for new Alzheimer’s blood test (BioPharma Dive, 2026-08-25)
- Roche commits to lean-mass preservation with Hanmi obesity deal (BioPharma Dive, 2026-08-25)
- Formation Bio taps Biogen, Pfizer alum to tackle R&D’s ‘boring middle’ (BioPharma Dive, 2026-08-07)
- Argenx jumps on Phase 3 data for blockbuster Vyvgart (BioPharma Dive, 2026-08-07)